Conference item icon

Conference item

ARCII: Nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy (CRT) in locally-advanced pancreatic cancer (LAPC)–mechanism and clinical outcomes

Abstract:

Background: In LAPC, additional benefit of CRT over chemotherapy is uncertain. Optimising local therapy for a subset that never develops distant disease may prolong survival. Nelfinavir is thought to enhance radiosensitivity through hypoxia reduction by increasing tumour blood flow. Methods: A non-randomised, single centre phase II study, in FDG-PET-selectedpatients withhistologically proven LAPC. CRT consisted of: nelfinavir 1250 mg bd (days -3 to 45); gemcitabine 300 mg/m2 & cisplatin 3...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1200/jco.2015.33.15_suppl.e15279

Authors


More by this author
Institution:
University of Oxford
Oxford college:
St John's College
Role:
Author
Expand authors...
Publisher:
American Society of Clinical Oncology Publisher's website
Journal:
Journal of Clinical Oncology Journal website
Volume:
33
Issue:
15 suppl
Host title:
Journal of Clinical Oncology
Publication date:
2017-01-31
DOI:
EISSN:
1527-7755
ISSN:
0732-183X
Source identifiers:
539727
Keywords:
Pubs id:
pubs:539727
UUID:
uuid:36b83003-b251-4b3a-912a-809df62a09d9
Local pid:
pubs:539727
Deposit date:
2017-01-03

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP